Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 10/20 | 0.38 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137923 | 0.88 | TLR4 (0.48) | TLR4LY96LMNAKMT2A | |
| SCHEMBL21137861 | 0.80 | MAPT (0.34) | TLR4LY96 | |
| SCHEMBL25957451 | 0.77 | TLR4 (0.49) | TLR4LY96LMNAKMT2A | |
| SCHEMBL21137926 | 0.76 | PYGB (0.33) | TLR4LY96 | |
| SCHEMBL23104821 | 0.76 | TLR4 (0.46) | TLR4LY96LMNAKMT2A | |
| SCHEMBL21137974 | 0.76 | TLR4 (0.46) | TLR4LY96LMNAKMT2A | |
| SCHEMBL21138007 | 0.75 | TLR4 (0.55) | TLR4LY96LMNAKMT2A | |
| SCHEMBL21137980 | 0.71 | PYGB (0.40) | TLR4LMNA | |
| SCHEMBL28855878 | 0.71 | PYGB (0.40) | TLR4LMNA | |
| SCHEMBL17689315 | 0.70 | TLR4 (0.52) | TLR4LY96LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | TLR4 896/4885LY96 3825/4885LMNA 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.